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the desired effect. Recently, the use of medications containing clostebol 
acetate has led to the suspension of several athletes in various sports. 
Previous studies have showed that urine can result positive in case of 
single intake of a banned substance, including unintentional consumption 
of steroids. In this context, hair test can contribute to exculpation of 
athletes by demonstrating alternative administration or contamination. The 
development and validation of a UHPLC-MS/MS method to detect clostebol 
and clostebol acetate in hair is hereby presented. Some real cases of 
athletes sanctioned for clostebol use, in which we analyzed hair samples to 
follow-up investigations of doping control laboratories and obtain useful 
elements to understand the origin of clostebol intakes, and two forensic 
cases of anabolic drugs abuse, are also presented and discussed. In real 
head and body hair samples, clostebol acetate could be detected in the low 
pg/mg range. As is typical of hair analysis, the interpretation of the 
quantitative findings may be challenging, and even more in sports owing to 
the lack of systematic studies. However, the results can be used to produce 
evidence contrary to any ruling issued against the athletes by the 
appropriate sports body, so to possibly obtain a diminished sanction. 
Because the sport authorities do not make a distinction among 
circumstances or means of administration of anabolic compounds, athletes 
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Abstract 
Clostebol is a synthetic anabolic androgenic steroid, with potential use as a performance-enhancing 
drug if taken for long periods in order to produce the desired effect. Recently, the use of 
medications containing clostebol acetate has led to the suspension of several athletes in various 
sports. Previous studies have showed that urine can result positive in case of single intake of a 
banned substance, including unintentional consumption of steroids. In this context, hair test can 
contribute to exculpation of athletes by demonstrating alternative administration or contamination. 
The development and validation of a UHPLC-MS/MS method to detect clostebol and clostebol 
acetate in hair is hereby presented. Some real cases of athletes sanctioned for clostebol use, in 
which we analyzed hair samples to follow-up investigations of doping control laboratories and 
obtain useful elements to understand the origin of clostebol intakes, and two forensic cases of 
anabolic drugs abuse, are also presented and discussed. In real head and body hair samples, 
clostebol acetate could be detected in the low pg/mg range. As is typical of hair analysis, the 
interpretation of the quantitative findings may be challenging, and even more in sports owing to the 
lack of systematic studies. However, the results can be used to produce evidence contrary to any 
ruling issued against the athletes by the appropriate sports body, so to possibly obtain a diminished 
sanction. Because the sport authorities do not make a distinction among circumstances or means of 
administration of anabolic compounds, athletes should be warned not to use clostebol-containing 
medications.  
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Introduction 
Clostebol, also known as 4-chlorotestosterone, is a weak synthetic anabolic androgenic steroid, with 
potential use as a performance-enhancing drug. For this reason, it is currently banned by the World 
Anti-Doping Agency
1
. For doping purposes and remarkable anabolic effects, clostebol is typically 
used as an ester, such as clostebol acetate, caproate, and propionate. Its intake usually occurs either 
by oral ingestion (as a tablet) or by intra-muscular injection, the latter generating high clostebol 
concentrations in biological samples. Even when clostebol is consumed in micro-doses (i.e., 
generating low levels of its main metabolite in urine), its intake should be maintained for some 
weeks in order to produce the desired effect. As clostebol acetate, it is also contained in balm and 
cream products, the most common being Trofodermin
®
. In recent years, the alleged use of clostebol 
led to the suspension of a number of athletes in various sports 
2
. Italy is one of the countries with 
the highest anti-doping rule violations involving this substance. This is not surprising, since Italy is 
one of few countries (another one is Brazil) who sell clostebol-containing medicines for 
dermatologic and gynecologic treatments. For example, the US Food and Drug Administration does 
not allow the inclusion of anabolic agents in any prescription 
3
. The same occurs in France and in 
most European countries. Incidental clostebol contamination in athletes after sexual intercourse 
3
 or 
from contaminated food 
4,5
 was also demonstrated in a few circumstances. 
Several cases of Adverse Analytical Finding (AAF) for banned doping agents detected in urine 
required the use of hair analysis to provide complementary information and understand the origin of 
the positive finding 
6-8
. As a matter of fact, the major disadvantage of urinalysis is that it provides 
only short term information of the individual’s drug consumption and does not ascertain sustained 
drug abuse 
9
. Thus, urine analysis is not particularly effective at identifying the athletes who partake 
in long term steroids use during the training periods and cease to take them prior of competition, 
resulting in a drug-free period sufficient to give negative results 
10
. In an opposite scenario, urine 
analysis may yield a positive result when a single intake of a banned substance occurred, including 
unintentional steroids consumption 
11,12
. In the latter case, the hair specimen would turn out 
negative. Although hair testing is not suitable to overrule a positive urine finding, it can 
significantly contribute to the exculpation of innocent athletes by demonstrating alternative 
administration pathways or contamination risks 
13
. Recently, this role of hair testing has been 
demonstrated in a case where hair analysis allowed the discrimination between the mycotoxin 
zearalenone and its urinary metabolite zeranol, which is banned for its anabolic properties 
14
.  In the 
present study, we developed a UHPLC-MS/MS method to detect clostebol and clostebol acetate in 
hair and applied this method to three real cases of athletes sanctioned for clostebol use, in order to 
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follow-up investigations of doping control laboratories and obtain useful elements to understand the 
origin of these positive findings, and two forensic cases in which some anabolic drugs abuse was to 
be assessed.  
 
EXPERIMENTAL 
Materials  
Chemical reagents, including methanol and acetonitrile (ACN), were purchased from Sigma-
Aldrich (Milan, Italy). Clostebol and testosterone-d3 were purchased from Steraloids (USA). 
Clostebol acetate was purchased from Sigma-Aldrich (Milan, Italy). Ultrapure water was obtained 
by a Milli-Q Millipore system (Bedford, MA, U.S.A.). A Precellys 24 Tubes Homogenizer (Bertin 
Pharma, Montigny-Le-Bretonneux, France) equipped with six 2.8 mm metal beads was used for 
hair milling. Stock standard solutions of analytes and internal standard (IS), were prepared in 
methanol at a concentration of 1 mg/mL and stored at −20°C in dark vials. Working methanolic 
solutions containing all the analytes at different concentrations were prepared by mixing the stock 
solutions at the proper dilution. The working solutions were used to spike negative hair samples at 
various levels. 
Instrumental conditions  
All analyses were performed on a Shimadzu Nexera 30 UHPLC-system (Shimadzu, Duisburg, 
Germany) interfaced to a Sciex API 5500 triple quadrupole mass spectrometer (Sciex, Darmstadt, 
Germany) with an electrospray Turbo Ion source operating in the positive ion mode (ESI+). A 
Waters BEH C18 column 100 × 2.1 mm i.d. × 1.8 µm, protected by a C18 guard column, was used 
for the separation of analytes. The column oven was maintained at +45 °C, and the elution solvents 
used were water/ammonium formate 5 mM (solvent A) and acetonitrile/ammonium formate 5 mM 
(solvent B). The mobile phase eluted under the following conditions (A/B; v/v): initial 90:10 ratio 
for 0.5 min, then linear gradient to 10:90 in 7 min; final isocratic condition at 90% B for 0.5 min. 
The flow rate was 0.5 mL/min. The MS system was operated in the selected reaction monitoring 
mode (SRM). In order to establish appropriate SRM conditions, each analyte was individually 
infused into the ESI capillary, while the declustering  potential (DP) and the entrance potential (EP) 
were adjusted to maximize the intensity of the [M–H]
+
 species. The collision offset voltage (CE) 
was adjusted to preserve approximately 10 % of the precursor ion, and the cell exit potentials (CXP) 
were also optimized. Each SRM transition was maintained during a time window of ±10.0 s around 
the expected retention time of the corresponding analyte, and the SRM target scan time (i.e.,sum of 
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dwell times for each SRM cycle) was 0.30 s, including pause times of 5 ms between consecutive 
SRM transitions. The best results were obtained using a source block temperature of +600 °C and 
an ion-spray voltage of 3800 V. Both Q1 and Q3 were operated at unit mass resolution. The gas 
settings were as follows: curtain gas 35.0 psi, collision gas 8.0 psi, ion source gas GS1 45.0 psi, and 
ion source gas GS2 55.0 psi. The Analyst 1.5.2 (Sciex) software was used for data processing. All 
analytes and IS, their corresponding retention time, SRM transitions, and potentials are presented in 
Table 1. 
Sample preparation 
About 50 mg of hair was twice-washed with dichloromethane and methanol (2 mL, vortex mixed 
for 3 min). After complete removal of the solvent wash, the hair was dried at room temperature by a 
gentle nitrogen flow and subsequently pulverized using a metal beads mill. The samples were then 
fortified with 5 µL of testosterone-d3 at 250 pg/µl, yielding a final concentration of 25 pg/mg. 
Sample extraction was carried out by addition of 1 mL of methanol, vortex shaking for 0.5 min, 
centrifugation at 4000 rpm for 1 min, to ensure the complete immersion of the matrix into the 
solvent, and final incubation at 55°C for 15 h. Lastly, the organic phase was collected and 
evaporated to dryness under a gentle stream of nitrogen and mild heating (70°C) using a Techne 
Sample Concentrator (Barloworld Scientific, Stone, UK). The residue was dissolved in a 50 µL 
methanol/ACN 1:1 solution, transferred into a vial and centrifuged at 4000 rpm for 10 min. A 5 µL 
aliquot was injected into the UHPLC–MS/MS system. 
Validation 
The analytical method was validated in accordance with the criteria and recommendations of 
international standard and international guidelines 
15
. The following parameters were investigated: 
specificity, selectivity, linearity range, detection and quantification limits (LOD and LOQ), intra-
assay and inter-assay precision and accuracy. The calibration process was conducted with an 
optimized procedure, requiring the preparation of three replicates of the calibration curves for the 
two analytes on three different days for a total of nine calibration curves for each analyte. The data 
from each specific calibration curve were quantified using a calibration curve obtained on a 
different day, allowing to manage each set of data as independent. Therefore, 9 samples (from 9 
different batches) per each calibration level were employed to estimate the previously cited 
validation parameters. Carry-over and matrix effect were also investigated. 
Specificity 
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A pool of five blank hair samples obtained from different healthy volunteers was prepared without 
spiking and analyzed as described above. The occurrence of possible interferences from 
endogenous substances was tested by monitoring the SRM chromatograms characteristic for each 
investigated compound at the expected retention time interval. The S/N was measured on the less 
intense mass transition at the expected analyte retention time. The noise was measured from the end 
of the peak till ±0.05 min after it for each analyte. A S/N<3 was considered satisfactory in order to 
verify the method’s specificity. 
Selectivity 
The repeatability of relative peak intensities for the transitions of each analyte was determined on 
five replicates of the pooled blank hair sample fortified at two concentration levels (10 and 100 
pg/mg). To assess selectivity, one qualifying transition was monitored, in addition to the primary 
transition.  
Linearity, LOD and LOQ 
The linear calibration model was checked by analyzing blank hair samples spiked with the working 
solution at five concentration levels (1, 10, 25, 50, 100 pg/mg). The calibration was completed by 
internal standardization. The linear calibration parameters were evaluated using the least squares 
regression method; several significance tests were performed to evaluate linearity, including lack-
of-fit test, analysis of variance (ANOVA), Mandel's test, and homo- vs. heteroscedasticity tests (see 
Table 2a). Determination coefficient (R
2
), adjusted determination coefficient (Adj R
2
), relative 
standard deviation of the slope, normality of the standardized residuals, and deviation from back-
calculated concentrations were also evaluated. The limit of detection (LOD) and the limit of 
quantitation were estimated with the Hubaux-Vos’ approach 
16
, which consider the uncertainty in 
the signals and concentrations associated with the calibration set. In-house developed spreadsheets, 
together with the routines developed by Desharnais et al. 
17
, were employed to evaluate these 
parameters and perform their relative significance tests.  
Precision and accuracy 
For all analytes, intra- and inter-day precision (expressed as percent variation coefficient, CV%) 
and accuracy (expressed as bias %) were evaluated at three concentration levels. The samples 
prepared for the evaluation of linearity, LOD and LOQ parameters were used, thus consisting of 
nine replicates (prepared and analyzed in three different days) of blank hair samples spiked with the 
standard solutions at the lowest calibration point (close to LOQ values), at intermediate calibration 
Page 7 of 19
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
level, and the highest calibration point, i.e. 1, 25 and 100 pg/mg concentrations. Intra-day and inter-
day precision parameters were considered satisfactory when CV% values turned below 15%. 
Satisfactory accuracy (in terms of bias %) was achieved when the experimentally determined 
average concentration lied within ±15% from the expected value. 
Carry-over 
The background chromatographic profiles for each analyte were monitored during the analysis of a 
blank hair sample injected for five times after the chromatographic run of a spiked blank hair 
sample containing all the analytes at 250 pg/mg concentration. To assure the absence of any carry-
over, the same criteria adopted to verify the specificity requirements had to be fulfilled. 
Matrix effect 
The matrix effect was calculated relatively to the ISTD, by comparing the peak area ratio between 
analyte and ISTD obtained from spiked hair samples, with the corresponding ratio obtained from a 
pure methanol solution, at the same concentrations. In this case, the matrix effect is expected to be 
partly compensated by a well-matched internal standard, i.e. the isotopically-marked analyte, 
whenever possible, or the one having the closest RT to the analyte, so as to undergo similar 
interference from the matrix. The matrix effect was calculated as the mean value obtained from five 
different hair sources. The percent difference represented either matrix suppression (values below 
100%) or matrix enhancement (values above 100%) 
18
. 
 
RESULTS 
Validation 
The optimized UHPLC-MS/MS method allowed the simultaneous determination of the two analytes 
plus the IS. The whole chromatographic run, comprehensive of the time required for column re-
equilibration, was completed in 9.0 min. Three SRM transitions were selected for each analyte. 
Validation results are presented in Table 2a and 2b.  
Specificity and Selectivity 
SRM chromatograms from negative hair samples showed no interfering signals at the retention time 
where the analytes were expected to elute. Thus, all specificity tests proved successful. Variations 
of relative qualifier ion intensities did not exceed ±20% with respect to the corresponding control 
and were considered acceptable, as well the retention times.  
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Linearity, LOD and LOQ 
The trend of the variance associated to the tested calibration points (i.e. homoscedasticity vs. 
heteroscedasticity) was evaluated. A weighting factor equal to (1/x
2
), where x represents the 
concentration of the calibration point, was adopted for both clostebol and clostebol acetate because 
the data points distribution turned heteroscedastic. The Mandel’s test suggested a linear regression 
model for both the target analytes. Then, both lack-of-fit and ANOVA tests turned successful for 
clostebol, while only lack-of-fit test was not passed for clostebol acetate. Table 2a reports a 
summary of the observed results, including the Adj R
2
 values of the regression models. LOD and 
LOQ values estimated by Hubaux-Vos’ methodology are reported, too. In particular, LOD values 
were0.3 pg/mg for clostebol and 1.1 pg/mg for clostebol acetate, while LOQ values lied at 0.6 
pg/mg and 2.1 pg/mg, respectively. The calculated LODs were experimentally confirmed with one 
blank hair sample spiked at the estimated LODs concentrations.  
Precision and accuracy 
Intra-day precision, inter-day precision and accuracy parameter results are reported in Table 2b. 
They showed satisfactory intra-day repeatability, as the percent variation coefficient (CV%) turned 
lower than 15% for all the spiked analytes at low, medium and high concentration (i.e. 1, 25 and 
100 pg/mg), with the exception of the lowest calibration point of clostebol that showed a CV% 
equal to 20%, but a consistent average value of 0.9 pg/mg and a standard deviation of 0.1 pg/mg. 
Also inter-day repeatability results proved fully satisfactory, as CV% values were within 15% or 
lower for all the spiked analytes at both low, medium and high concentrations, with once again the 
exception of the lowest calibration point of clostebol that showed a CV% equal to 30%. Finally, the 
accuracy parameter turned optimal, as the percent bias were within few percent in almost all cases, 
with maximum experimental errors of -9% for clostebol and -4% for clostebol acetate.  
 
Carry-over 
The background chromatographic profiles of the main transitions for each analyte, monitored 
during the analysis of blank hair extracts injected after samples spiked at the highest analytes 
concentration, did not show the presence of any significant signal (i.e., the S/N value was always 
<3) at the retention times expected for both  analytes.  
Matrix effect 
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The effect of the real hair matrix appeared to be not significant for both analytes tested. In general, 
the good linearity observed in the calibration plots demonstrated that the observed matrix effect is 
proportionally constant, i.e., does not depend on the analytes' concentrations. 
 
REAL CASES 
Case 1 
A professional boxer, male, 33 years old, was found positive in urine after an in-competition control 
(clostebol metabolite: 1 ng/mL). He claimed to have applied an ointment containing clostebol 
acetate (Trofodermin
®
, 500 mg/100 gr) to his wife for 4-5 days, one time per day, in order to heal 
her infected shoulder tattoo. He also claimed he did not know that the cream was containing a 
banned substance. Last application was done one week before the antidoping control. Three months 
later, we collected arm hair and leg hair from the athlete, and head hair from his wife. Head hair and 
chest hair from the athlete were too short to cover the period of interest therefore they were not 
collected. All samples were black-colored. Arm and leg hair were analyzed in their total length, 
while the wife’s’ hair was segmented according to the period of interest. A full description of the 
collected samples is presented in Table 3. 
Arm hair and leg hair collected from the athlete resulted positive to clostebol acetate (respectively 3 
pg/mg and 5 pg/mg). Only one segment of wife’s hair was positive (13 pg/mg). Clostebol was not 
detected in any sample. The chromatogram from the analysis of the leg hair sample is shown in 
Figure 1.  
 
Case 2 
A 45-years-old long-distance female runner was found positive after an in-competition urine control 
(clostebol metabolite 15 ng/mL). She admitted the use of Trofodermin
®
 before the competition to 
medicate some foot lesion. She also claimed she did not know that the cream was containing a 
banned substance. A hair sample, black colored, was collected 45 days after the antidoping control 
and analyzed after segmentation according to the period of interest. A full description of the 
collected samples is presented in Table 3.   
Only one hair segment resulted positive for clostebol acetate at the concentration of 21 pg/mg. 
Clostebol was not detected in any segment.  
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Case 3 
A young male diver, 18 years old, was found positive after an in-competition urine control 
(clostebol metabolite 1 ng/mL). The use of Trofodermin
®
 or other clostebol-containing medicines 
was not acknowledged. Several nutritional supplements and medications were also tested for the 
presence of clostebol. Possible contamination from beef meat eaten in a Japanese restaurant few 
days before the antidoping control was also accounted for the positive result. We collected head hair 
and pubic hair 30 days after the antidoping control. All samples were black colored. Pubic hair was 
analyzed in its total length, while the head hair was segmented according to the period of interest. A 
full description of the collected samples is presented in Table 3.   
All samples were negative for clostebol and clostebol acetate, including hair samples, nutritional 
supplements and medications. 
 
Case 4 
A man, aged 41 years was under a divorce procedure. The man declared discontinuation of any 
anabolic drug that he admitted to use previously to improve his performance in the amateur sport 
practice within a fitness center. A hair test was requested by the judge to discriminate the unceasing 
use of anabolic drugs from their discontinuation in order to decide which parent should be 
responsible of two children. A full description of the collected samples is presented in Table 3.  
Unfortunately, a segmental analysis was not feasible because of the low quantity of hair available. 
The test executed on the entire 3-cm hair sample revealed the presence of clostebol acetate at 9 
pg/mg. 
 
Case 5 
A man, aged 35 with aggressive behaviour, was accused to have allegedly raped a young girl. He 
declared the use of anabolic drugs to the judge. He also declared that the violence was caused by an 
enhanced libido induced by his abuse of anabolic steroids. The laboratory was requested to verify 
his statement. A full description of the collected samples is presented in Table 3.   
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The hair sample was found positive to clostebol acetate (6 pg/mg). Other anabolic steroids, 
including stanozolol, methandienone and boldenone, were detected in the same hair sample (data 
not shown).  
A full description of results is presented in Table 3.   
 
Discussion 
Synthetic anabolic steroids have attracted significant scientific attention as target compounds in hair 
analysis for both doping control and a variety of different forensic contexts 
13
. In this study, we 
report for the first time the detection of clostebol acetate in hair in the pg/mg range. In hair analysis, 
the interpretation of the quantitative findings is typically challenging, and even more in antidoping 
analysis (almost exclusively conducted on body fluids) owing to the lack of systematic studies. For 
example, it is known that the amount of hydrophobic and basic drugs detected in hair strongly 
depends on the hair color, with dark and red hair showing higher drug incorporation than blond and 
white hair 
19
. Nevertheless, data from doping and forensic cases involving anabolic steroids are 
progressively collected in the scientific literature, allowing more reliable interpretation to be made 
13
. The majority of reported cases dealt with steroid administration in bodybuilding or powerlifting, 
resulting in quite high hair concentrations. For example, stanozolol was reported to range from 5 to 
86.3 pg/mg 
10,20
, while metandienone from 7 to 108 pg/mg 
21
. With the limitations cited above, it is 
common opinion that the detection of drugs at low pg/mg range in hair samples may represent 
single or occasional exposure to the drug, while higher levels usually indicate regular or therapeutic 
administration, although there is no inter-individual correlation between the frequency and dose of 
drug intake and hair concentration 
19
. In the following paragraphs, five real cases involving 
clostebol are discussed and tentatively interpreted with the help of hair analysis, three of which 
complemented the documentation of the AAF obtained from urine testing. 
In case #1, the athlete claimed he had been in unaware contact with clostebol while applying a 
cream to his wife. The hair results proved that both subjects had been exposed to the banned 
compound, with the woman’s hair showing higher concentrations than the man’s. The athlete 
provided two types of body hair, namely arm and leg hair, which usually cover a longer detection 
window 
22
 and yield higher concentration than head hair. Considering the differences in clostebol 
acetate concentrations, the type of hair specimens, and the similar dark color, the hypothesis of 
external unaware contamination could be sustained as plausible. After the athlete appealed, these 
evidences were partially accepted and the sentence was reduced from 24 to 15 months. 
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In case #2, the athlete admitted the use of Trofodermin
®
 claiming she was not aware that its 
composition included a banned substance. Clostebol acetate was detected in only one hair segment, 
chronologically corresponding to the declared period of the cream use. The detected concentration 
was relatively high, coherently with a repeated direct application of the cream onto the severe lesion 
she wanted to cure. The other analyzed segment was completely negative, excluding the protracted 
use of clostebol outside the cited period, i.e., for anabolic purposes. After the athlete appealed, these 
evidences were partially accepted and the sentence was reduced from 24 to 15 months. 
In case #3, the athlete could not provide any explanation for the positive result, nor any other 
possible source of unaware clostebol intake was identified after the analysis of several 
pharmaceuticals and supplements habitually or occasionally used by the athlete. However, all hair 
samples collected from the athlete turned out negative for clostebol and clostebol acetate, unlike the 
cases previously described, including case #1, where exposure to clostebol had been limited and 
transitory. Therefore, the hypothesis of accidental exposure, possibly from contaminated food, was 
supportively sustained. The athlete was cleared from the doping violation charges.  
In cases #4 and 5, the hair test was used for forensic purposes and ordered by a Judge. In both cases, 
the results documented clostebol use, with low concentrations in hair being likely related to 
occasional exposure. Both subjects were charged for drug diversion.  
CONCLUSIONS 
The detection of clostebol/clostebol acetate in consecutive hair segments can prove the regular use 
of this drug for anabolic purposes. On the other hand, the detection of clostebol/clostebol acetate at 
low concentration levels in only one hair segment, chronologically corresponding to the time of the 
ascertained AAF, can sustain the occasional exposure to the drug, provided that an alternative 
source of unaware intake is identified. Under such circumstances, the deliberate doping offense can 
be ruled out and the athlete’s defense may obtain a charge remission. Because the IOC does not 
make a distinction among circumstances or means of administration of anabolic compounds, it is 
important that the athletes are warned against the use of clostebol-containing medications and aware 
of medical treatments used by their partners, especially in countries where clostebol is present in 
widely distributed balms and creams. While keeping the full athletes’ responsability to control 
every potential source of banned drugs, hair analysis can nevertheless give support to those who 
were inadvertently contaminated, in order to produce evidence proving that their exposure had not 
been deliberate and in particular not aimed to improve their athletic performances. When hair 
analysis supports the latter claim, the athlete has the chance to obtain a diminished sanction. 
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Table 1. SRM transitions and corresponding potentials for the target compounds and internal standard detection 
Compound 
RT  
(min) 
Precursor Ion 
[M+H]
+
 
DP (V) 
 Target   Qualifier 1  Qualifier 2 
 Fragment CE (V) CXP (V)  Fragment CE (V) CXP (V)  Fragment CE (V) CXP (V) 
 Clostebol 4.9 323.1  87  143.0 33 14  131.0 33 5  269.3 24 9 
 Clostebol Acetate 6.4 365.1  81  143.0 38 10  305.2 21 5  323.2 23 12 
 Testosterone-d3 4.3 292.2  47  97.2 26 5         
DP, Declustering potential; CE, Collision Energy; CXP, Cell Exit Potential. 
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Table 2a. Results of calibration data and linearity tests (Adjusted Regression Coefficient R
2
, Lack-of-Fit, ANOVA and Mandel's test) over the 
calibration interval (i.e., 1-100 pg/mg); LOD and LOQ values calculated by the Hubaux-Vos’ method. 
Target analyte Model 
Adjusted 
R
2 
Lack-of-Fit 
(Fcrit = 2.60) 
ANOVA test 
(Ftab=3.84) 
Mandel’s test 
(Fcrit= 2.12) 
LOD 
(pg/mg) 
LOQ 
(pg/mg) 
Clostebol 
Linear  
(weighted, 1/x2) 
0.9995 0.26 0.91 1.35 0.3 0.6 
Clostebol acetate 
Linear  
(weighted, 1/x
2
) 
0.9942 3.48 1.15 1.94 1.1 2.1 
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Table 2b. Intraday/Interday precision (CV%) and accuracy (bias%) for the analytes tested 
 
 Clostebol  Clostebol Acetate 
  Intraday  Interday  Intraday  Interday 
Calibration 
level 
 Precision 
(CV%) 
Accuracy 
(bias%) 
 Precision 
(CV%) 
Accuracy 
(bias%) 
 Precision 
(CV%) 
Accuracy 
(bias%) 
 Precision 
(CV%) 
Accuracy 
(bias%) 
Low level 
(1 pg/mg) 
 
20 −9 
 
30 −8 
 
14 −4 
 
15 −1 
    
Medium Level 
(25 pg/mg) 
 
12 −1 
 
9 −1 
 
12 −4 
 
12 −4 
    
High Level 
(100 pg/mg) 
 
6 −1 
 
14 −1 
 
9 −3 
 
14 −2 
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Table 3 Summary of results obtained from real cases 
Case, Subject Specimen Total Length (cm) Analyzed Length (cm) Clostebol Clostebol acetate 
#1, boxer Arm hair 3 Full length Negative 3 pg/mg 
#1, boxer Leg hair 3 Full length Negative 5 pg/mg 
#1, boxer’s wife Head hair 12 
Segment 0-2 Negative Negative 
Segment 2-5 Negative 13 pg/mg 
Segment 5-12 Negative Negative 
#2, runner Head hair 10 
Segment 0-2 Negative 21 pg/mg 
Segment 2-10 Negative Negative 
#3, diver Head hair 2 
Segment 0-1 Negative Negative 
Segment 1-2 Negative Negative 
#3, diver Pubic hair 3 Full length Negative Negative 
#4, amateur  Head hair 3 Full length Negative 9 pg/mg 
#5, alleged rapist Head hair 4 Full length Negative 6 pg/mg 
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Figure 1. LC-MS/MS chromatogram of the positive clostebol acetate finding in the leg hair sample from case 
#1 (below) compared to a negative control (above). The chromatograms of deuterated internal standard is 
also shown.  
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